TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $10.90 Average Price Target from Brokerages

Key Points

• TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has received a consensus rating of "Buy" from seven analysts, with an average 12-month price target of $10.90.
• The company's recent quarterly earnings showed an EPS of ($0.27), falling short of the consensus estimate, while revenue of $11.21 million exceeded expectations.
• Significant institutional interest is noted, with Gilder Gagnon Howe & Co. LLC raising its stake in TriSalus by 32.1% during the second quarter.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has received a consensus recommendation of "Buy" from the seven brokerages that are covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $10.90.

Separately, Wall Street Zen raised TriSalus Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday.

TriSalus Life Sciences Trading Up 0.5%

NASDAQ TLSI traded up $0.03 during mid-day trading on Friday, reaching $4.91. 17,296 shares of the company's stock traded hands, compared to its average volume of 71,979. The company has a fifty day simple moving average of $4.63 and a 200-day simple moving average of $5.09. TriSalus Life Sciences has a 1-year low of $3.42 and a 1-year high of $5.88. The company has a market cap of $244.61 million, a price-to-earnings ratio of -4.17 and a beta of 0.49.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). The business had revenue of $11.21 million during the quarter, compared to the consensus estimate of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. Equities research analysts forecast that TriSalus Life Sciences will post -1.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. bought a new stake in shares of TriSalus Life Sciences in the 1st quarter worth approximately $55,000. Bank of America Corp DE lifted its holdings in shares of TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock worth $894,000 after purchasing an additional 178,298 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after purchasing an additional 5,936 shares during the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of TriSalus Life Sciences by 16.0% in the 2nd quarter. Bridgeway Capital Management LLC now owns 75,400 shares of the company's stock worth $411,000 after purchasing an additional 10,400 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of TriSalus Life Sciences in the 1st quarter worth approximately $187,000. Institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.